Cyberonics — Merger or Acquisition (September 2015)
37 slides from Cyberonics's merger presentation, Sep 10, 2015
Slide 1: Slide 1
Slide 2: Creating LivaNova, a Premier Global Medical Technology Company
CREATING LIVANOVA, A PREMIER GLOBAL MEDICAL TECHNOLOGY COMPANY
Slide 3: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders This presentation is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solici
Slide 4: Cyberonics SORINGROUP
Cyberonics SORINGROUP DF soRING: Cyberonics
Slide 5: Sorin Group and Cyberonics to create LivaNova, a leading global medtech company
• Diverse, market-leading product portfolio to drive shareholder value • Technical and commercial scale across geographies to enhance revenue growth • Focused innovation platform to exploit market opportunities and accelerate product development in Heart Failure, Sleep Apnea and Percutaneous Mitral
Slide 6: Cyberonics
Cyberonics
Slide 7: Compelling strategic rationale
Leadership in Large and Growing Markets Opportunities in Three Multi-Billion Dollar Specialty Markets Global Scale and Geographic Diversification Highly Complementary Technologies Strong Balance Sheet to Execute Plan Compelling strategic rationale
Slide 8: Cyberoni¢s’
Cyberoni¢s’
Slide 9: Cyberonics and Sorin at a glance
FY revenues Cyberonics and Sorin at a glance 1) FY 2015 figures as of April 24 , 2015 for Cyberonics. FY 2014 figures as of December 2014 for Sorin translated at an average exchange rate of $1.33/€1 Sutureless valve (Perceval ) and Goal- Directed-Perfusion system CRT optimization system (SonR ) Neur
Slide 10: SORIN Cyberofi¢s'
SORIN Cyberofi¢s'
Slide 11: Global scale and geographical diversification
Global scale and geographical diversification São Paulo, Brazil Cyberonics Manufacturing and offices Sorin Manufacturing and R&D Vancouver, BC Denver, CO Houston, TX Costa Rica Mirandola, Italy Meylan, France Saluggia, Italy Munich, Germany Clamart, France Louvain-la-Neuve, Belgium Dominican Republi
Slide 12: Cyberonics
Cyberonics SORINGROUP O O Cyberoni¢s
Slide 13: Highly complementary businesses
Highly complementary businesses … 1) FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014 figures as of 31st December 2014 for Sorin translated at an average exchange rate of $1.33/€1 Geography Business Unit Revenues : $292m Neuromodulation 100% International 19% US 81% Revenues : $998m Int
Slide 14: Cyberonics
Cyberonics
Slide 15: Diversified product portfolio and broader geographical reach
Europe 43% US 36% Rest of World 21% $1.3bn ...leading to diversified product portfolio and broader geographical reach Pro forma revenues by geography Pro forma revenues by business 1) FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014 figures as of 31st December 2014 for Sorin translated
Slide 16: Position
Position Cyberoni¢s
Slide 17: Bringing together global leaders in Cardiac Surgery and Neuromodulation
• Bringing together global leaders in Cardiac Surgery and Neuromodulation • Leveraging an innovative Cardiac Rhythm Management platform Leadership in large and growing markets CARDIAC SURGERY NEUROMODULATION CRM Cardiopulmonary global leader – #1 in Heart-lung machines – #1 in Oxygenators Leading pl
Slide 18: saniiqedes Sujapel sales
2 ic 2 o 2 > (6) saniiqedes Sujapel 9 sales S2UOIJAQAD | WHAT NiGSS 4
Slide 19: Highly complementary technologies and selling capabilities
Wireless MRI-Compatibility Remote Monitoring ICD Leads VNS Science and Expertise Algorithms Closed- loop Rechargeable Highly complementary technologies and selling capabilities Shared technologies Complementary commercialization capabilities Implantable electronics Neuromodulation Heart Failure Slee
Slide 20: # SORINGROUP Cyberonics
# SORINGROUP Cyberonics
Slide 21: Opportunities in billion dollar specialty markets
Heart Failure (HF) Sleep Apnea Percutaneous Mitral • Accelerated development and commercialization of new product categories • The combined opportunities leverage Cyberonics’ ability to develop markets and Sorin’s geographical reach Opportunities in billion dollar specialty markets Potential market
Slide 22: SORINGHOUP
SORINGHOUP Cyberoni¢s
Slide 23: Operating synergies driving significant incremental value
Manufacturing Neuromodulation revenue Heart failure Corporate overhead R&D optimization ~$80 million of annual pre-tax operating synergies to be delivered by the end of 2018 Operating synergies driving significant incremental value Cyberonics’ leverage of Sorin’s commercialization network Capitalizi
Slide 24: Slide 24
Slide 25: Experienced, world-class management team
Experienced, world-class management team André-Michel Ballester Chief Executive Officer Dan Moore Non-Executive Chairman of the Board Ed Andrle Strategy, Business Development and New Ventures/Emerging Therapies Brian Sheridan General Counsel Pritpal Shinmar Global Market Access David Wise HR & IT De
Slide 26: Cyberonics
Cyberonics
Slide 27: Transaction overview
LivaNova PLC domicile and listing • Incorporated in the UK and UK tax resident • Dual listed on Nasdaq and London Stock Exchange Exchange ratio • 1:1 of LivaNova stock for Cyberonics shareholders • 0.0472:1 of LivaNova stock for Sorin shareholders Ownership • Cyberonics shareholders: ~ 54% • Sorin s
Slide 28: @e@OG
@e@OG Cyberonics
Slide 29: Transaction timeline: closing expected in Q4 2015
Unanimous approval by BoD and deal announcement 26 Feb US Antitrust approval 14 April LivaNova management and integration team announced 12 May Sorin EGM approved proposed merger 26 May End of 15-day Sorin Shareholder Withdrawal Right period 12 June End of 60-day Sorin Creditor Rights period 27 July
Slide 30: Cyberonics
Cyberonics
Slide 31: Driving significant shareholder returns
Revenue growth acceleration Synergies EPS impact Balance Sheet implications Driving significant shareholder returns • Stronger and more diversified platform for growth • Significant revenue potential from highly complementary Heart Failure programs • Leverage Sorin’s commercialization network for Ne
Slide 32: Cyberoni¢s
Cyberoni¢s
Slide 33: Sorin Q2 2015 Results
Value Change Sorin Q2 2015 Results * Ended June 30, 2015 • Robust revenue growth in Cardiac Surgery (€146.7m, +5.5%°) – Strong momentum in cardiopulmonary • Solid results in Cardiac Rhythm Management (€68.3m, +4.6%°) – Growth in Low-Voltage • Successful roll-out of Inspire in Europe, the US and Japa
Slide 34: DPE soRINGS Cyberoni¢és
DPE soRINGS Cyberoni¢és
Slide 35: Cyberonics Q1 2016 Results
Value Change Cyberonics Q1 2016 Results * Ended July 24, 2015 • Record net sales of $81m over the quarter • Record U.S. net product sales of $67.7m (+15%) • Driven by very strong demand for the AspireSR® generator • International net sales up 11.4% on a constant currency basis • Initial launch of Vi
Slide 36: Cyberoni¢s
Cyberoni¢s
Slide 37: Contacts
Contacts FOR SORIN GROUP: Investors: Demetrio Mauro CFO Sorin Group Tel: +39 02 69969 512 e-mail: [email protected] Francesca Rambaudi Director, Investor Relations Sorin Group Tel: +39 02 69969 716 e-mail: [email protected] Media: Gabriele Mazzoletti Director, Corporate Communi